| Item Type | Name |
|
Academic Article
|
Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study.
|
|
Academic Article
|
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
|
|
Academic Article
|
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
|
|
Academic Article
|
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
|
|
Academic Article
|
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
|
|
Academic Article
|
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
|
|
Academic Article
|
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
|
|
Academic Article
|
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.
|
|
Academic Article
|
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
|
|
Academic Article
|
A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.
|
|
Academic Article
|
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
|
|
Concept
|
Cisplatin
|
|
Academic Article
|
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
|
|
Academic Article
|
Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer.
|
|
Academic Article
|
A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report.
|
|
Academic Article
|
Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
|
|
Academic Article
|
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
|
|
Academic Article
|
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
|
|
Academic Article
|
Is there still a role for induction chemotherapy in locally advanced head and neck cancer?
|
|
Academic Article
|
Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer.
|
|
Academic Article
|
Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
|
|
Academic Article
|
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
|
|
Academic Article
|
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
|
|
Academic Article
|
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
|
|
Academic Article
|
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
|
|
Academic Article
|
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
|
|
Academic Article
|
Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer.
|
|
Academic Article
|
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
|
|
Academic Article
|
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
|
|
Academic Article
|
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
|
|
Academic Article
|
Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb).
|
|
Academic Article
|
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
|
|
Academic Article
|
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
|
|
Academic Article
|
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
|
|
Academic Article
|
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
|
|
Academic Article
|
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
|
|
Academic Article
|
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
|
|
Academic Article
|
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
|
|
Academic Article
|
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
|
|
Academic Article
|
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
|
|
Academic Article
|
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
|
|
Academic Article
|
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
|
|
Academic Article
|
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
|
|
Academic Article
|
Outcomes for olfactory neuroblastoma treated with induction chemotherapy.
|
|
Academic Article
|
Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas.
|
|
Academic Article
|
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
|
|
Academic Article
|
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.
|
|
Academic Article
|
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
|
|
Academic Article
|
Role of induction chemotherapy for oral cavity squamous cell carcinoma.
|